• Disc Medicine priced an upsized public offering of common stock expected to raise $450 million in gross proceeds before expenses.
• The offering comprises 6,000,000 shares at $75 per share.
• Underwriters have a 30-day option to purchase up to 900,000 additional shares at the offering price, less underwriting discounts and commissions.
• Closing is expected on October 22, 2026, subject to customary conditions.
• Net proceeds will support clinical development, potential bitopertin commercialization for EPP and XLP, other pre-commercialization activities and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610202052PRIMZONEFULLFEED9850027) on October 21, 2026, and is solely responsible for the information contained therein.